249 related articles for article (PubMed ID: 34996121)
21. Dose-Related Effectiveness of Andexanet Alfa for Reversal of Apixaban Anticoagulation in a Porcine Polytrauma Model.
Rayatdoost F; Braunschweig T; Schöchl H; Rossaint R; Grottke O
Thromb Haemost; 2024 Jan; 124(1):20-31. PubMed ID: 37604188
[TBL] [Abstract][Full Text] [Related]
22. Andexanet alfa for the reversal of factor Xa inhibitors.
Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
24. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
25. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
[TBL] [Abstract][Full Text] [Related]
26. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
Siepen BM; Polymeris A; Shoamanesh A; Connolly S; Steiner T; Poli S; Lemmens R; Goeldlin MB; Müller M; Branca M; Rauch J; Meinel T; Kaesmacher J; Z'Graggen W; Arnold M; Fischer U; Peters N; Engelter ST; Lyrer P; Seiffge D
Int J Stroke; 2024 Jun; 19(5):506-514. PubMed ID: 38264861
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
[TBL] [Abstract][Full Text] [Related]
28. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
Abdulrehman J; Eikelboom JW; Siegal DM
Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
[TBL] [Abstract][Full Text] [Related]
29. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
30. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
[TBL] [Abstract][Full Text] [Related]
31. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Ruff CT; Giugliano RP; Antman EM
Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
[TBL] [Abstract][Full Text] [Related]
32. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Rogers KC; Finks SW
Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
[TBL] [Abstract][Full Text] [Related]
33. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
Klok FA; Huisman MV
Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
[TBL] [Abstract][Full Text] [Related]
34. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban.
Abuan I; Wong KH; Bolinske B; Hale KS
J Pharm Technol; 2019 Jun; 35(3):119-125. PubMed ID: 34860981
[No Abstract] [Full Text] [Related]
35. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
[TBL] [Abstract][Full Text] [Related]
36. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
[TBL] [Abstract][Full Text] [Related]
37. Andexanet alfa for the treatment of hemorrhage.
Cervi A; Crowther M
Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870
[TBL] [Abstract][Full Text] [Related]
38. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Sartori M; Cosmi B
J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
40. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
